Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

Research output: Contribution to journalArticle

Standard

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur. / Geisler, Christian H.; Kolstad, Arne; Laurell, Anna; Jerkeman, Mats; Raty, Riikka; Andersen, Niels S.; Pedersen, Lone B.; Eriksson, Mikael; Nordstrom, Marie; Kimby, Eva; Bentzen, Hans; Kuittinen, Outi; Lauritzsen, Grete F.; Nilsson-Ehle, Herman; Ralfkiaer, Elisabeth; Ehinger, Mats; Sundstrom, Christer; Delabie, Jan; Karjalainen-Lindsberg, Marja-Liisa; Brown, Peter; Elonen, Erkki.

In: British Journal of Haematology, Vol. 158, No. 3, 2012, p. 355-362.

Research output: Contribution to journalArticle

Harvard

Geisler, CH, Kolstad, A, Laurell, A, Jerkeman, M, Raty, R, Andersen, NS, Pedersen, LB, Eriksson, M, Nordstrom, M, Kimby, E, Bentzen, H, Kuittinen, O, Lauritzsen, GF, Nilsson-Ehle, H, Ralfkiaer, E, Ehinger, M, Sundstrom, C, Delabie, J, Karjalainen-Lindsberg, M-L, Brown, P & Elonen, E 2012, 'Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur', British Journal of Haematology, vol. 158, no. 3, pp. 355-362. https://doi.org/10.1111/j.1365-2141.2012.09174.x

APA

CBE

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, Pedersen LB, Eriksson M, Nordstrom M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundstrom C, Delabie J, Karjalainen-Lindsberg M-L, Brown P, Elonen E. 2012. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur. British Journal of Haematology. 158(3):355-362. https://doi.org/10.1111/j.1365-2141.2012.09174.x

MLA

Vancouver

Author

Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Jerkeman, Mats ; Raty, Riikka ; Andersen, Niels S. ; Pedersen, Lone B. ; Eriksson, Mikael ; Nordstrom, Marie ; Kimby, Eva ; Bentzen, Hans ; Kuittinen, Outi ; Lauritzsen, Grete F. ; Nilsson-Ehle, Herman ; Ralfkiaer, Elisabeth ; Ehinger, Mats ; Sundstrom, Christer ; Delabie, Jan ; Karjalainen-Lindsberg, Marja-Liisa ; Brown, Peter ; Elonen, Erkki. / Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur. In: British Journal of Haematology. 2012 ; Vol. 158, No. 3. pp. 355-362.

RIS

TY - JOUR

T1 - Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

AU - Geisler, Christian H.

AU - Kolstad, Arne

AU - Laurell, Anna

AU - Jerkeman, Mats

AU - Raty, Riikka

AU - Andersen, Niels S.

AU - Pedersen, Lone B.

AU - Eriksson, Mikael

AU - Nordstrom, Marie

AU - Kimby, Eva

AU - Bentzen, Hans

AU - Kuittinen, Outi

AU - Lauritzsen, Grete F.

AU - Nilsson-Ehle, Herman

AU - Ralfkiaer, Elisabeth

AU - Ehinger, Mats

AU - Sundstrom, Christer

AU - Delabie, Jan

AU - Karjalainen-Lindsberg, Marja-Liisa

AU - Brown, Peter

AU - Elonen, Erkki

PY - 2012

Y1 - 2012

N2 - Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early based on the median observation time of 4 years results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6.5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7.4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at as ISRCTN 87866680.

AB - Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early based on the median observation time of 4 years results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6.5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7.4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at as ISRCTN 87866680.

KW - mantle cell lymphoma

KW - autologous stem cell transplant

KW - high-dose AraC

KW - rituximab

KW - pre-emptive therapy

UR - https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.12006

U2 - 10.1111/j.1365-2141.2012.09174.x

DO - 10.1111/j.1365-2141.2012.09174.x

M3 - Article

VL - 158

SP - 355

EP - 362

JO - British Journal of Haematology

T2 - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -